Amgen (AMGN): BMO Sees Inceased Competitive Risk to KYPROLIS
Tweet Send to a Friend
BMO Capital maintained a Market Perform rating on Amgen (NASDAQ: AMGN) with a price target of $139. Earlier Takeda ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
